Degludec: the new ultra-long insulin analogue.

about

Preparation of Selenoinsulin as a Long-Lasting Insulin Analogue.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.

P2860

Q48296760-D24BFFF6-6F67-4611-9578-CD069C5CBD22 Q53449720-E12F5245-E937-446D-9CDB-2368C878D6E7

P2860

Degludec: the new ultra-long insulin analogue.

Item

http://www.wikidata.org/entity/Q41564970

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Degludec: the new ultra-long insulin analogue.

@en

type

Item

label

Degludec: the new ultra-long insulin analogue.

@en

prefLabel

Degludec: the new ultra-long insulin analogue.

@en

P1476

Degludec: the new ultra-long insulin analogue.

@en

P2093

Freddy Goldberg Eliaschewitz

http://www.w3.org/2001/XMLSchema#string

Marcos Antonio Tambascia

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec

Insulin formulations--a review

Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics.

Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell.

Insulins today and beyond.

A review of the pharmacological properties of insulin degludec and their clinical relevance.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.

P2888

s13098-015-0037-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13098-015-0037-0

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279728896

http://www.w3.org/2001/XMLSchema#string

P6179

1001925702

http://www.w3.org/2001/XMLSchema#string

P698

26136850

http://www.w3.org/2001/XMLSchema#string

P932

4486707

http://www.w3.org/2001/XMLSchema#string

Degludec: the new ultra-long insulin analogue.

about

P2860

P2860

Degludec: the new ultra-long insulin analogue.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932